InMed Pharmaceuticals is a publicly traded clinical-stage company that trades on the Nasdaq under the symbol INM. InMed is developing a pipeline of cannabinoid-based pharmaceutical drug candidates, initially focused on the therapeutic benefits of cannabinol (CBN), in diseases with high unmet medical need. The Company is dedicated to delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. InMed employs a highly scientific approach to designing and developing medicines, which will help unlock the full potential of cannabinoid pharmaceuticals. InMed employs a highly scientific approach with a proven management team with a track record of success to designing and developing medicines, which will help unlock the full potential of cannabinoid pharmaceuticals.

Learn more at www.inmunebio.com

Presentation

Research Coverage

Edison Investment Research

Recent Events

DON'T SEE YOUR CITY?

Request an event

BACK TO EVENTS